2 unknown, 1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Immunicon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer 21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab - Colorectal Cancer | Phase 3 | Completed | Dutch Colorectal Cancer Group | 750 | 2005-06-01 | 2012-02-02 |
| Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy Phlebotomy - Hormone Refractory Prostate Cancer, Prostate Cancer | Unknown | Immunicon | 276 | 2004-12-01 | 2009-07-28 | |
| Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer Phlebotomy - Colorectal Cancer, Neoplasm Metastasis | Unknown | Immunicon | 486 | 2004-03-01 | 2008-03-19 |
Colorectal Neoplasms (2) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Phlebotomy (2) · Bevacizumab (1) · Cetuximab (1) · Oxaliplatin (1)
United States (2) · Netherlands (1)
C JA Punt, MD PhD (1) · Derek Raghavan, M.D. (1) · Ken Pienta, MD (1) · Steven Cohen, MD (1)
PMID 23014524, PMID 18272912, PMID 19196673, PMID 21803570, PMID 23692811, PMID 30557370